Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
A Phase 3 trial evaluating HLX10 in combination with Carboplatin and Pemetrexed with or without HLX04 versus Carboplatin plus Pemetrexed in …
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
Clinical trial update for HLX301, a TIGIT×PDL1 bispecific, in locally advanced or metastatic solid tumors and non-small cell lung cancer acr…
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial update on GLS-012 and GLS-010 in advanced non-small cell lung cancer to assess safety, tolerability, and preliminar…
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab [Phase 1, Phase 2]
A Phase 1/2 trial evaluating letetresgene autoleucel (lete-cel) T-cells targeting NY-ESO-1/LAGE-1a, alone or with pembrolizumab, in advanced…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 2, Phase 3]
A multicenter trial evaluated paclitaxel and carboplatin with or without cediranib in stage III or IV non-small cell lung cancer, with compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy [Phase 1, Phase 2]
Clinical trial update for a MET/VEGFR2 inhibitor (GSK1363089) with or without erlotinib in locally advanced or metastatic non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy [Phase 2]
Phase 2 trial update of Reolysin in previously treated advanced/metastatic non-small cell lung cancer patients receiving standard salvage th…
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer [Phase 1]
Phase 1 trial evaluating anlotinib hydrochloride in combination with AP for advanced non-squamous non-small-cell lung cancer has completed w…
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating bintrafusp alfa plus chemotherapy in EGFR-mutant non-small cell lung cancer resistant to tyrosine kinase inhibitors…
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating regorafenib in combination with methotrexate for KRAS-mutated recurrent or metastatic non-small cell lung cancer ha…
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib [Phase 2]
A Phase 2 trial evaluated local ablative therapy for oligoprogressive, EGFR-mutated non-small cell lung cancer after treatment with osimerti…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab [Phase 1]
Phase 1 dose-escalation trial evaluating intra-tumoral NIS measles virus with atezolizumab in recurrent non-small cell lung cancer; study te…
-
CLINICAL_TRIALS trial_result · 2023-07-18Clinical Trial Update: LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 trial investigating LMB-100 followed by pembrolizumab in adults with mesothelin-expressing non-squamous non-small cell lung cancer; …
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating FLT3 ligand and CD40 agonist antibody with stereotactic radiotherapy for lung cancer (non-small cell/non…
-
CLINICAL_TRIALS trial_result · 2023-07-12Clinical Trial Update: Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) [Phase 2]
Phase 2 trial update for preoperative gefitinib in EGFR-mutant II-IIIa non-small cell lung cancer (ECTOP-1001) completed.
-
CLINICAL_TRIALS trial_result · 2023-07-07Clinical Trial Update: A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer [Phase 2]
Phase 2 clinical trial evaluating ONM-100 as an intraoperative fluorescence imaging agent for cancer detection has completed enrollment with…
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: Alectinib in Combination With Bevacizumab in ALK Positive NSCLC [Phase 2]
Phase 2 trial evaluating alectinib in combination with bevacizumab for ALK-positive non-squamous non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib [Phase 2]
Phase 2 exploratory study of erlotinib in combination with SNDX-275 in non-small cell lung cancer patients progressing on erlotinib; trial t…
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating apatinib and fluzoparib with or without adebrelimab in previously treated TP53-mutant advanced non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. [Phase 2]
Phase 2 neoadjuvant trial evaluating canakinumab or pembrolizumab as monotherapy or in combination for early-stage non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 study of CAN04 in combination with various chemotherapy regimens for advanced solid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions [Phase 2]
Phase 2 study of tarloxotinib in NSCLC with EGFR Exon 20 insertion or HER2-activating mutations and other solid tumors with NRG1/ERBB fusion…
-
CLINICAL_TRIALS trial_result · 2023-06-26Clinical Trial Update: Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC [Phase 1, Phase 2]
Phase 1/2 trial updates for dose-escalation of RMC4630 with cobi in relapsed/refractory solid tumors and RMC4630 with osi in EGFR+ locally a…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy [Phase 3]
Phase III trial evaluating canakinumab with docetaxel in adults with non-small cell lung cancer as second or third-line therapy; study termi…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Plasmodium Immunotherapy for Lung Cancer [Phase 1, Phase 2]
A clinical trial update on a plasmodium immunotherapy approach for lung cancer, currently in Phase 1 and Phase 2.